Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 90.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,853 shares of the biopharmaceutical company's stock after selling 146,535 shares during the period. SG Americas Securities LLC's holdings in Theravance Biopharma were worth $128,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Hsbc Holdings PLC bought a new position in Theravance Biopharma during the second quarter valued at $108,000. XTX Topco Ltd bought a new position in Theravance Biopharma during the 2nd quarter valued at about $129,000. State Board of Administration of Florida Retirement System raised its position in Theravance Biopharma by 28.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company's stock worth $203,000 after purchasing an additional 4,990 shares during the period. Los Angeles Capital Management LLC bought a new stake in Theravance Biopharma in the second quarter worth about $286,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Theravance Biopharma by 30.7% during the first quarter. BNP Paribas Financial Markets now owns 33,458 shares of the biopharmaceutical company's stock valued at $300,000 after buying an additional 7,851 shares during the period. 99.10% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on TBPH shares. Leerink Partnrs downgraded Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 6th. TD Cowen decreased their target price on Theravance Biopharma from $10.00 to $9.00 and set a "hold" rating for the company in a research report on Tuesday, August 6th. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Theravance Biopharma in a report on Monday, September 16th. StockNews.com lowered shares of Theravance Biopharma from a "buy" rating to a "hold" rating in a report on Saturday, August 10th. Finally, Leerink Partners cut shares of Theravance Biopharma from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $15.00 to $10.00 in a research report on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $13.75.

Insider Buying and Selling

In other news, major shareholder Eli Samaha bought 999,800 shares of the business's stock in a transaction that occurred on Wednesday, August 7th. The shares were purchased at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the transaction, the insider now directly owns 9,511,150 shares in the company, valued at approximately $74,186,970. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 6.90% of the stock is owned by company insiders.

Theravance Biopharma Trading Down 1.0 %

Shares of TBPH traded down $0.09 during mid-day trading on Friday, hitting $8.55. The company's stock had a trading volume of 69,732 shares, compared to its average volume of 356,208. The company's 50-day moving average is $8.22 and its 200-day moving average is $8.75. Theravance Biopharma, Inc. has a 52-week low of $7.44 and a 52-week high of $11.71. The firm has a market capitalization of $415.81 million, a price-to-earnings ratio of -9.94 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.25). The firm had revenue of $14.26 million for the quarter, compared to analysts' expectations of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. During the same period in the previous year, the company posted ($0.28) earnings per share. As a group, sell-side analysts predict that Theravance Biopharma, Inc. will post -1.04 earnings per share for the current fiscal year.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.